Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
出版年份 2013 全文链接
标题
Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
作者
关键词
-
出版物
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
Volume 46, Issue 8, Pages 650-658
出版商
FapUNIFESP (SciELO)
发表日期
2013-10-01
DOI
10.1590/1414-431x20133003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3)
- (2012) Prabodh K Kandala et al. BMC Medicine
- Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells
- (2011) D Bose et al. BRITISH JOURNAL OF CANCER
- HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition
- (2011) Karuppaiyah Selvendiran et al. CANCER BIOLOGY & THERAPY
- Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets
- (2011) Caroline Gest et al. CANCER LETTERS
- Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells
- (2011) Shuling Huang et al. CANCER LETTERS
- A Potent Oncolytic Adenovirus Selectively Blocks the STAT3 Signaling Pathway and Potentiates Cisplatin Antitumor Activity in Ovarian Cancer
- (2011) Zhiqiang Han et al. HUMAN GENE THERAPY
- Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells
- (2011) P Yue et al. ONCOGENE
- Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer
- (2011) Rachel Haviland et al. PLoS One
- Oxygenation inhibits ovarian tumor growth by down-regulating STAT3 and cyclin-D1 expressions
- (2010) Karuppaiyah Selvendiran et al. CANCER BIOLOGY & THERAPY
- Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation
- (2010) Kiyomi Takaishi et al. CANCER SCIENCE
- Effects of Siltuximab on the IL-6-Induced Signaling Pathway in Ovarian Cancer
- (2010) Y. Guo et al. CLINICAL CANCER RESEARCH
- The status of platinum anticancer drugs in the clinic and in clinical trials
- (2010) Nial J. Wheate et al. DALTON TRANSACTIONS
- Anticancer Efficacy of a Difluorodiarylidenyl Piperidone (HO-3867) in Human Ovarian Cancer Cells and Tumor Xenografts
- (2010) K. Selvendiran et al. MOLECULAR CANCER THERAPEUTICS
- Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling
- (2010) S. R. Walker et al. MOLECULAR PHARMACOLOGY
- Oct4 and LIF/Stat3 Additively Induce Krüppel Factors to Sustain Embryonic Stem Cell Self-Renewal
- (2009) John Hall et al. Cell Stem Cell
- Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways
- (2008) Aisha Siddiqa et al. BMC CANCER
- Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids
- (2008) Sylvain L'Espérance et al. BMC GENOMICS
- Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6β1 integrin
- (2008) Michelle Colomiere et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
- (2008) Dan G. Blazer et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started